VEGFR‐2 protein levels were almost absent in tumour samples, and this correlated with improved OS, but again not only in bevacizumab‐treated patients, suggesting that optimal bevacizumab response does not rely on VEGFR‐2 expression.83 This evidence concerns the gene KDR and neoplasm.